# Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on Chemotherapy

> **NCT03007407** · PHASE2 · COMPLETED · sponsor: **NSABP Foundation Inc** · enrollment: 33 (actual)

## Conditions studied

- Colorectal Cancer Metastatic

## Interventions

- **DRUG:** durvalumab
- **DRUG:** Tremelimumab

## Key facts

- **NCT ID:** NCT03007407
- **Lead sponsor:** NSABP Foundation Inc
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-31
- **Primary completion:** 2019-04-18
- **Final completion:** 2019-08-09
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2022-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03007407

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03007407, "Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on Chemotherapy". Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/clinical/NCT03007407. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*